Beta Bionics Posts 54% Sales Surge, Boosts Gross Margin to 55.4%, but FDA Warning Weighs
Beta Bionics posted $100.3M in 2025 net sales, up 54%, expanded gross margin to 55.4% and doubled its user base to 20,000. It reported a 42% Q4 operating expense increase, received an FDA warning letter and expects short-term revenue headwinds from free islet pharmacy conversions and Q1 seasonality.
1. Record Sales and Margin Expansion
Beta Bionics achieved $100.3 million in net sales for 2025, representing a 54% year-over-year increase. Full-year gross margin expanded to 55.4%, with Q4 margin reaching 59%, driven by higher manufacturing volumes, while the company doubled its user base by adding 20,000 new patients and secured formulary agreements with all major US pharmacy benefit managers.
2. Rising Expenses and Regulatory Setback
Operating expenses climbed 42% in Q4 2025 due to sales force expansion and increased R&D investments in its patch pump program and bi-hormonal system trials. The company received an FDA warning letter citing deficiencies in its complaint handling and quality systems, which may necessitate further corrective actions and spending.
3. Free Islet Pharmacy Strategy and Near-Term Headwinds
Beta Bionics has launched a pharmacy channel strategy giving away islets initially, creating short-term revenue drag that management has factored into its 2026 guidance. The company also anticipates a sequential decline in Q1 2026 revenue from deductible resets and seasonality, while transitioning reporting on new patient starts to a less transparent format.